autologous blood and marrow transplantation - Blog Science ...

74 Chapter 2: ALL
Table 1. Patient characteristics
Data
Unpurged
autoBMT
Purged
autoBMT PBSCT
Number 19 48 12
Age (years): median (range) 24(18-49) 28 (18-52) 28 (14-49)
Sex: male/female 13/6 30/18 12/-
Immunophenotype
B-lineage 13 33 6
T-lineage 4 15 6
Not available 2 — —
Initial WBC xl0 9
/L: median (range) 6 (0.7-295) 14 (0.8-650) 17(5-70)
Days to CR1 : median (range) 32 (20-150) 30(15-150) 45 (26-116)
Months CR-SCT: median (range) 4 (0.5-15) 5.8(0.2-18) 4.2 (0.5-8)
harvesting of an insufficient number of BM cells (ra=17). The main characteristics
of the series appear in Tables 1 and 2.
As shown in Table 2, most patients receiving an autoSCT in CR1 had one or
more poor prognosis features. These adverse characteristics were age >35 years
(n=10), white blood cell counts (WBC) >30X 10 9
/L (n=12), null or B (surface Ig+)
immunophenotype (n-9), complete remission obtained in more than 5 weeks
(n=22), Philadelphia chromosome (Ph +
) (n=5), or t(4;l 1) ALL (n=l). Table 2 also
reflects the number of patients autografted in first remission with none, one, and
two or more poor prognosis features.
All patients in second or subsequent remission and those in relapse were
considered to have poor-risk ALL, since adults in these stages are unlikely to be
cured with chemotherapy. In these categories, an established prognostic factor is
the duration of first remission. The number of patients autografted in CR2 with first
remission